Premium
Antiandrogenic agents as monotherapy in advanced prostatic carcinoma
Author(s) -
Soloway Mark S.,
Matzkin Haim
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19930201)71:3+<1083::aid-cncr2820711430>3.0.co;2-1
Subject(s) - antiandrogens , medicine , testosterone (patch) , libido , androgen , estramustine , oncology , potency , antiandrogen , urology , prostate cancer , gynecology , cancer , hormone , prostate disease , in vitro , biochemistry , chemistry
Pure antiandrogens have a quality‐of‐life advantage over other androgen ablation methods in the treatment of patients with prostatic cancer because they do not reduce the serum testosterone and therefore do not have a marked inhibitory effect on libido and potency. The long half‐life of two of the three currently studied pure antiandrogens permits once‐a‐day administration, which should enhance patient compliance. With continued administration, there is a gradual rise in serum testosterone, and the clinical impact of this requires additional study using randomized Phase III trials. Proper stratification of patients at entry into such studies with documentation of various prognostic factors will add statistical value and enable physicians to draw better conclusion on the relative efficacy of these agents.